Page 9 - Pharma Sector

Jubilant Life Sciences Q1 profit declines 52%, revenue at Rs Rs 1,893 cr

Consolidated total revenue from the operations of the company stood at Rs 1,892.92 crore for the quarter under consideration. It was Rs 2,181.86 crore for the same period a year ago

Lupin launches generic rheumatoid arthritis drug 'Leflunomide' in US market

Drug maker Lupin on Wednesday said it has launched Leflunomide tablets, used to treat rheumatoid arthritis, in the US market. The company has launched the product in 10 mg and 20 mg strengths after receiving the approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a statement. The product would be manufactured at drug maker's Pithampur (Unit I) facility in Madhya Pradesh, it added. The Mumbai-based company's product is the generic equivalent of Sanofi-Aventis US LLC's Arava tablets and is indicated for the treatment of adults with active rheumatoid arthritis (RA). As per IQVIA MAT June data, Leflunomide tablets had an annual sales of around USD 42 million in the US.

Abbott gets DCGI nod for once-a-day heart failure, angina treatment drug

Global healthcare firm Abbott on Wednesday said it has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina. The company plans to launch Ivabradine prolonged release tablets in the Indian market in the coming weeks, Abbott said in a statement. This formulation will be more convenient for patients, which will help facilitate treatment adherence with the aim to improve health outcomes, it added. The formulation has been developed at Abbott's innovation & development (I&D) centre in Mumbai, the statement said. "Adherence to therapy is a critical factor to maximize the overall health of people with chronic heart failure or chronic stable angina. We have used the best technology and science to develop this new dosage formulation," Abbott Regional Medical Director Balagopal Nair said. The convenient once-a-day formulation will help improve overall ...

World Coronavirus Dispatch: EU vaccine makers seek immunity from lawsuits

Morgan Stanley turns cautious on bonds, why globalisation will survive, ozone's effectiveness in neutralising Covid, and other pandemic-related news across the globe

Pharmacy consolidation may disrupt domestic drug market: Credit Suisse

The report says if chemists are allowed to replace doctor's prescription with a generic drug, firms with high exposure to chronic therapeutic drugs will be impacted more

API segment supports growth for large generic pharma players in Q1

However, price correction could lead to growth moderation in the near term

Domestic pharma market to grow 12-14% in 3 years, exports by 8-14%: KPMG

The country ranks as the third-largest pharma market globally by volume and 13 largest by value

PE/VC investments drop 51% to $4.1 billion as big deals shrink in July

According to the IVCA-EY report, July recorded 10 large deals (value greater than $100 million) worth $3.1 billion compared to 13 large deals worth $7.1 billion in July 2019

Pharma rally may lose steam as valuations factor in near term gains

Recovery in India business, traction in new launches in the US market are needed to sustain gains

Domestic pharmaceutical industry to clock 4-6% growth in FY21: Icra

The domestic pharma industry has been posting slow growth numbers since March after the Covid-19 pandemic hit prescription generation

Rothschild bullish on India, expects to close more deals in H22020

Domestic deal activity managed to remain in the green during the first half, thanks to the unprecedented stake sale by Reliance Industries in Jio Platforms, between April and June, worth nearly $15 bn

Face-to-face selling hits a wall

By understanding the new normal, you can recalibrate your sales machine to become even more productive

Next 10 yrs to be India's golden moment: Silicon Valley venture capitalist

India has received foreign direct investment of over $20 billion in the last few months during the coronavirus pandemic

India needs holistic ecosystem to rebuild API manufacturing capacity: PwC

The Chinese API industry has an inherent advantage because of economies of scale and support from the Chinese government

MPs ask govt to promote inexpensive drugs, tighten reins on pharma lobby

A dozen of the 30 MPs, who are members of the parliamentary standing committee on home affairs, headed by Congress's Anand Sharma, attended the meeting

Green shoots seen in June pharma sales as domestic market grows 2.4%

The turn around follows deep decline in sales in the preceding months; July sales likely to be flat

Pharma SMEs will overcome short-term disruptions: CRISIL SME Tracker

Short-term disruptions include high input costs and various operational challenges.

Policy flip-flops may puncture India's image as 'pharmacy of the world'

India supplies almost 20 per cent of the medicines consumed by the world. Every third tablet in the US market is from India

Why India's automobile, pharma sectors are not ready to wean off China

India relies on China for products such as electronic components and drug ingredients because it cannot make them or source them elsewhere as cheap.

The discontents of decoupling

Economic delinking with China makes no sense for India; investment, growth and public welfare will suffer